Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
To report an Adverse Reaction directly to Chugai Pharma Europe Ltd or Roche Products Ltd please see the details below. Please aim to include details on the Product (name of product; either generic or brand name); Reporter (name and contact details); Patient (age/age group/gender); Event (describing the event in as much detail as you have available).
Report an Adverse Reaction to Chugai Pharma Europe Ltd
(for Akynzeo®, Aloxi® and Granocyte®)
Telephone: +44 (0) 20 8987 5600
Email: [email protected]
Report an Adverse Reaction to Roche Products Ltd
For Hemlibra®, Tecentriq® and Avastin®, please report side effects or adverse events to Roche following the guidance available here.
As Hemlibra, Tecentriq and Avastin are biological medicines, healthcare professionals should report adverse reactions by brand name and batch number.
For information about data processing within the scope of Pharmacovigilance, please refer to our Pharmacovigilance Privacy Notice.
The Yellow Card Scheme is run by the Medicines and Healthcare products Regulatory Agency (MHRA). The Scheme is used to collect information from Healthcare Professionals and patients on suspected Adverse Drug Reactions (ADRs). It is vital in helping the MHRA monitor the safety of the medicines and vaccines that are on the market.
Both Healthcare Professionals and patients can submit information through the Yellow Card website.
Reporting forms and information can be found at http://www.mhra.gov.uk/yellowcard.
The Summary of Product Characteristics for the products listed above can be found below:
C-GB-00000899 | Date of Preparation: December 2023
Chugai Pharma Europe Ltd takes great care over the information presented on this website, but it does not guarantee its accuracy, completeness, usefulness, etc. Furthermore, Chugai Pharma Europe Ltd will not be responsible for any damages resulting from the use of this website or the information presented on this website. For further details, please read the following “Privacy Statement” and “Important Information.”
Copyright © 2023 Chugai Pharma Europe Ltd. All rights reserved.
